Hybryte™ treatment studies presented at two medical conferences in march

Two presentations highlight data demonstrating hypericin photodynamic therapy potential with a preliminary comparison to current therapy princeton, n.j. , march 6, 2025 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its lead investigators for the cutaneous t-cell lymphoma (ctcl) and psoriasis programs are presenting findings from recent supportive trials with hybryte™ (synthetic hypericin) in the treatment of ctcl and sgx302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis.
SNGX Ratings Summary
SNGX Quant Ranking